Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT
1A
agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.
IRADYAN, M. A.;AROYAN, R. A.;ENGOYAN, A. P.;POGOSYAN, A. V.;STEPANYAN, G.+, XIM.-FARMATS. ZH., 24,(1990) N, S. 38-41
作者:IRADYAN, M. A.、AROYAN, R. A.、ENGOYAN, A. P.、POGOSYAN, A. V.、STEPANYAN, G.+
DOI:——
日期:——
DIHYDROIMIDAZOTHIAZOLE DERIVATIVES
申请人:Prosidion Limited
公开号:EP1851232A2
公开(公告)日:2007-11-07
[EN] DIHYDROIMIDAZOTHIAZOLE DERIVATIVES<br/>[FR] DERIVES DE DIHYDRO-IMIDAZOTHIAZOLE
申请人:PROSIDION LTD
公开号:WO2006085118A2
公开(公告)日:2006-08-17
[EN] Compounds of formula (I): or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity. [FR] L'invention concerne des composés de la formule (I), ou des sels pharmaceutiquement acceptables de ceux-ci, qui présentent un agonisme 5-HT1A, outre l'inhibition de la recapture de la noradrénaline et éventuellement l'inhibition de la recapture de 5-HT, et qui sont utilisés dans le traitement de l'obésité.
Structure and biological activity of phenacylthioimidazolines and 3-phenyl-5,6-dihydroimidazo[2,1-b]thiazoles
作者:M. A. Iradyan、R. A. Aroyan、A. P. Engoyan、A. V. Pogosyan、G. M. Stepanyan、F. G. Arsenyan、B. T. Garibdzhanyan